CANTON, Mass., June 21 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ), the leader in on-site oral fluid diagnostics announced today that Pete Phildius, Avitar's chairman and chief executive officer will present today at Friedland Capital's Biotech, Medical and Healthcare luncheon in Boston. The meeting will be held at 12:00 PM EDT at Radius Restaurant, 8 High Street, Boston, MA.
The presentation by Mr. Phildius will provide attendees of the Friedland Capital meeting with an update on Avitar's business and recent customer acquisitions.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Company Contact: PR Contact:
Peter Cholakis Monica Pandolfi
Avitar Technologies, Inc. Shift Communications